Affiliation:
1. Cancer Molecular Diagnostics, St James’s Hospital , Dublin , Ireland
Abstract
Teaser text (No Figure)
Pyoderma gangrenosum can be associated with haematological malignancies but rarely a myeloproliferative neoplasm. A review of requests for molecular detection of myeloproliferative neoplasm driver mutations in patients with pyoderma gangrenosum was performed and revealed that testing for these mutations is unwarranted in cases where there are no clinical, haematological or morphological features of a myeloproliferative neoplasm present.
Publisher
Oxford University Press (OUP)
Reference5 articles.
1. Pyoderma gangrenosum: a review of patient’s demographics, disease and treatment in 118 patients;Honigman;Australas J Dermatol,2022
2. Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation;Hermouet;Mediators Inflamm,2015
3. Pyoderma gangrenosum in association with Janus kinase 2 (JAK2 V617F) mutation;Palanivel;Clin Exp Dermatol,2013
4. Idiopathic myelofibrosis and pyoderma gangrenosum involving a mutation of Janus kinase 2 (JAK2 V617F), showing poor prognosis;Hideki;Eur J Dermatol,2013
5. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor;Nasifoglu;Br J Dermatol,2018